Challenges and opportunities for the next generation of cardiovascular tissue engineering
Challenges and opportunities for the next generation of cardiovascular tissue engineering
复制标题
DOI：
10.1038/s41592-022-01591-3
复制
发表时间：
2022-09-05
期刊：
影响因子：
48
通讯作者：
Wu, Joseph C.
中科院分区：
文献类型：
--
作者：
Cho, Sangkyun;Discher, Dennis E.;Wu, Joseph C.
在这个角度上，心脏组织工程领域的技术和挑战进行了讨论，并提出了克服这些挑战的策略。来自人类诱导多能干细胞的工程心脏组织为患者特异性疾病建模，药物发现和心脏修复提供了独特的机会。自从二十多年前引入第一个工程心脏以来，基于人类诱导多能干细胞的三维心脏类器官和心脏芯片系统现已成为基础心血管研究的支柱，成为研究基础人类病理生理学和发育的宝贵平台。然而，在该领域真正走向商业和临床翻译之前，仍有一些主要障碍有待解决。在这里，我们提供了一个快照的国家的最先进的方法在心脏组织工程，重点是在体外模型的人类心脏。展望未来，我们讨论了该领域的主要挑战和机遇，并提出了使工程心脏组织作为心脏病理生理学模型和治疗方法开发试验平台得到广泛接受的策略。
In this Perspective, technologies and challenges in the cardiac tissue engineering field are discussed and strategies to overcome these challenges are proposed.Engineered cardiac tissues derived from human induced pluripotent stem cells offer unique opportunities for patient-specific disease modeling, drug discovery and cardiac repair. Since the first engineered hearts were introduced over two decades ago, human induced pluripotent stem cell-based three-dimensional cardiac organoids and heart-on-a-chip systems have now become mainstays in basic cardiovascular research as valuable platforms for investigating fundamental human pathophysiology and development. However, major obstacles remain to be addressed before the field can truly advance toward commercial and clinical translation. Here we provide a snapshot of the state-of-the-art methods in cardiac tissue engineering, with a focus on in vitro models of the human heart. Looking ahead, we discuss major challenges and opportunities in the field and suggest strategies for enabling broad acceptance of engineered cardiac tissues as models of cardiac pathophysiology and testbeds for the development of therapies.